Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.
Also called NCT07776054
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 200 participants
- Sponsor
- Registry
-
NCT07776054
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT07776054. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2027-08-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Impact of SGLT2 Inhibitor After DC Cardioversion in Persistent AF With HFpEF
- Condition
- Atrial Fibrillation
- Condition
- SGLT2 Inhibitor
- Condition
- DC Cardioversion
- Intervention (Drug)
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct07776054- Content hash
f0951d568e8843cb077c28473e8313c3ba8cb8c417b2f6d14d97a8167a595c4b